BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Scavilla confirmed the acquisition of Nevro Corporation for $250 million, expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic ...

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Additionally, the analyst acknowledged that the performance of Nevro and Emerging Technologies could provide some support to Globus Medical’s Spine business. However, there is a belief that even ...

Looking ahead to 2025, Globus Medical has provided guidance that reflects both its standalone operations and the impact of its recent acquisition of Nevro Corp (NYSE:NVRO). The company expects net ...

Nevro technology has potential beyond its ... With no further questions, that concludes the Globus Medical’s earning call. Thank you for participating. You may now disconnect.

Joining today's call from Globus Medical will be Dan Scavilla ... In April, we completed the purchase of all shares of the Nevro Corporation for an all-cash transaction of $250 million.

Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position.

Zimmer Biomet announced today that it appointed Kevin Thornal as group president, global businesses and the Americas.

Zimmer Biomet named Kevin Thornal as group president for global business and the Americas, according to a May 27 news release. Mr. Thornal will join the company July 1. He was previously CEO and ...